[November 02, 2017]

Cigna Reports Strong Third Quarter 2017 Results, Raises Outlook

Cigna Corporation (NYSE: CI) today reported third quarter 2017 results with strong performance across the company's Global Health Care, Global Supplemental Benefits and Group Disability & Life segments.

"Cigna's third quarter results are driven by consistent, strong execution of our strategy to provide affordable and personalized solutions for our customers and clients around the globe," said David M. Cordani, President and Chief Executive Officer. "As we look ahead to 2018, we expect to drive continued innovation and growth as we deliver sustained value in a rapidly changing and dynamic environment."

Total revenues in the quarter were $10.4 billion, an increase of 5% over third quarter 2016, driven by continued growth in Cigna's targeted customer segments.

For the third quarter of 2017, shareholders' net income was $560 million, or $2.21 per share, compared with $456 million, or $1.76 per share, for the third quarter of 2016.

Cigna's adjusted income from operations¹ for the third quarter of 2017 was $716 million, or $2.83 per share, compared with $503 million, or $1.94 per share, for the third quarter of 2016. This reflects significantly increased earnings contributions from each of our business segments.

Reconciliations of shareholders' net income to adjusted income from operations¹ are provided on the following page, and on Exhibit 2 of this earnings release.

CONSOLIDATED HIGHLIGHTS

The following table includes highlights of results and reconciliations of consolidated operating revenues⁵ to total revenues and adjusted income from operations¹ to shareholders' net income:

• Third quarter 2017 shareholders' net income included special item¹ charges of $215 million after-tax, or $0.85 per share, predominantly associated with the previously disclosed early extinguishment of debt, compared with special item¹ charges in third quarter 2016 of $71 million after-tax, or $0.28 per share, for merger-related transaction costs and a litigation matter.
• Cash and marketable investments at the parent company were $1.7 billion at September 30, 2017 and $2.8 billion at December 31, 2016.
• Year to date, as of November 1, 2017, the Company repurchased 13.2 million shares of common stock for approximately $2.3 billion.

HIGHLIGHTS OF SEGMENT RESULTS

See Exhibit 2 for a reconciliation of adjusted income (loss) from operations¹ to shareholders' net income.

Global Health Care

This segment includes Cigna's Commercial and Government businesses that deliver medical and specialty health care products and services to domestic and multi-national clients and customers using guaranteed cost, retrospectively experience-rated and administrative services only ("ASO") funding arrangements. Specialty health care includes behavioral, dental, disease and medical management, stop loss and pharmacy-related products and services.

• Global Health Care results in the third quarter reflect strong performance led by our Commercial business.
• Third quarter 2017 premiums and fees increased 6% relative to third quarter 2016, driven by customer growth and specialty contributions in our Commercial business, partially offset by lower enrollment in our Government business, as expected.
• The medical customer base² at the end of the third quarter 2017 totaled 15.8 million, an increase of 619,000 customers year to date, driven by organic growth across our Commercial market segments.
• Third quarter 2017 adjusted income from operations¹ and adjusted margin, after-tax⁶ reflect strong medical and specialty results, continued effective medical cost management and operating expense discipline.
• Adjusted income from operations¹ for third quarter 2017 and second quarter 2017 included favorable prior year reserve development on an after-tax basis of $19 million and $36 million, respectively. Third quarter of 2016 did not have a meaningful amount of net prior year reserve development. Year-to-date 2017 adjusted income from operations¹ includes favorable prior year reserve development on an after-tax basis of $116 million.
• The Total Commercial medical care ratio⁸ ("MCR") of 78.6% for third quarter 2017 reflects strong performance and effective medical cost management in both our Employer and Individual books of business, as well as the impact of the health insurance tax moratorium.
• The Total Government MCR⁸ of 84.0% for third quarter 2017 reflects solid performance in our Medicare Advantage and Medicare Part D businesses.
• The third quarter 2017 Global Health Care operating expense ratio⁸ of 21.1% reflects the impact of the health insurance tax moratorium, business mix changes and continued effective expense management.
• Global Health Care net medical costs payable⁹ was approximately $2.52 billion at September 30, 2017 and $2.26 billion at December 31, 2016.

Global Supplemental Benefits

This segment includes Cigna's global individual supplemental health, life and accident insurance business, primarily in Asia, and Medicare supplement coverage in the United States.

Financial Results (dollars in millions, policies in thousands):

• Global Supplemental Benefits results continue to reflect the value created by affordable and personalized solutions delivered directly to individual consumers through a diversified set of distribution channels.
• Third quarter 2017 premiums and fees¹⁰ grew 12% over third quarter 2016, reflecting continued business growth.
• Third quarter 2017 adjusted income from operations¹ and adjusted margin, after-tax⁶ reflect business growth, favorable claims experience, particularly in South Korea, and effective operating expense management.

Group Disability and Life

This segment includes Cigna's group disability, life and accident insurance operations.

Financial Results (dollars in millions):

• Group Disability and Life results reflect the value created for our customers and clients through differentiated solutions that enhance health, productivity and sense of security.
• Third quarter 2017 adjusted income from operations¹ and adjusted margin, after-tax⁶ reflect favorable claims experience in our life business, and disability results consistent with our expectations.

Corporate & Other Operations

Adjusted loss from operations¹ for Cigna's remaining operations is presented below:

2017 OUTLOOK

Cigna's outlook for full year 2017 consolidated adjusted income from operations^1,3 is in the range of $2.60 billion to $2.65 billion, or $10.20 to $10.40 per share. Cigna's outlook excludes the impact of additional prior year reserve development and potential effects of any future capital deployment.⁴

The foregoing statements represent the Company's current estimates of Cigna's 2017 consolidated and segment adjusted income from operations^1,3 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

This quarterly earnings release and the Quarterly Financial Supplement are available on Cigna's website in the Investor Relations section (http://www.cigna.com/aboutcigna/investors). Management will be hosting a conference call to review third quarter 2017 results and discuss full year 2017 outlook beginning today at 8:30 a.m. EDT. A link to the conference call is available in the Investor Relations section of Cigna's website located at http://www.cigna.com/cignadotcom/aboutcigna/investors/events/index.page.

The call-in numbers for the conference call are as follows:

Live Call
(800) 369-1781 (Domestic)
(210) 234-0090 (International)
Passcode: 11022017

Replay
(800) 945-7247 (Domestic)
(203) 369-3951 (International)

It is strongly suggested you dial in to the conference call by 8:15 a.m. EDT.

Notes:

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release, and oral statements made with respect to information contained in this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income (loss) from operations outlook for 2017, on both a consolidated and segment basis; projected total revenue growth and global medical customer growth, each over year end 2016; projected growth in 2018 and beyond; projected medical care and operating expense ratios and medical cost trends; future financial or operating performance, including our ability to deliver personalized and innovative solutions for our customers and clients; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding Cigna's future beliefs, expectations, plans, intentions, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes, including those in our disability business; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and/or guaranty fund assessments; uncertainties surrounding participation in government-sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; uncertainty as to the outcome of the litigation between Cigna and Anthem, Inc. with respect to the termination of the merger agreement, the reverse termination fee and/or contract and non-contract damages for claims each party has filed against the other, including the risk that a court finds that Cigna has not complied with its obligations under the merger agreement, is not entitled to receive the reverse termination fee or is liable for breach of the merger agreement;, as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available on the Investor Relations section of www.cigna.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

(1) Adjusted income (loss) from operations is defined as shareholders' net income (loss) excluding the following after-tax adjustments: realized investment results; net amortization of other acquired intangible assets; and special items (identified and quantified on Exhibit 2).

(1) For additional information related to a one-time tax benefit of approximately $60 million recorded in the second quarter of 2017, please refer to Note 3 to the Consolidated Financial Statements in Cigna's Form 10-Q for the period ended September 30, 2017 expected to be filed on November 2, 2017.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005313/en/

[ Back To TMCnet.com's Homepage ]